# Ipamorelin Research: Mechanism, Pharmacokinetics, and the Trial Record > Ipamorelin research summarized: GHS-R1a selectivity, the ~2-hour human half-life, the rat bone-growth data, the failed postoperative-ileus trial, and the CJC-1295 / sermorelin / tesamorelin comparisons. Heavily cited. From the 1998 selectivity paper to the 2024 ferret cachexia study — each finding with its source. ## Start here Ipamorelin research breaks into three clean pieces. First, the mechanism: it switches on one specific receptor — the ghrelin receptor (GHS-R1a) on the pituitary gland — to release a burst of growth hormone, and it does so cleanly, without the cortisol bump that older peptides cause [1]. Second, the pharmacokinetics: a single human study measured how the body handles it, finding a half-life (time to clear half the dose) of about two hours and a growth-hormone burst that peaks near forty minutes [2]. Third, the outcomes: the one human trial that tested whether it helps a real condition — slow bowel recovery after surgery — did not beat a placebo [3]. The rest is animal data and chemistry. Each section below carries the studies behind it, and the full list is on the [Ipamorelin references](/references) page. ## Mechanism: selective growth-hormone release Ipamorelin selectively activates the growth hormone secretagogue receptor 1a (GHS-R1a), the receptor for the body's natural hunger hormone ghrelin, on pituitary somatotrophs. Receptor activation runs through a Gq/phospholipase-C cascade, raising intracellular calcium and triggering GH release. Because this pathway is separate from the GHRH pathway, the two can act together — the basis for combination protocols [1]. Its founding characterization is the defining result. In primary rat pituitary cells, anaesthetised rats, and conscious swine, ipamorelin released GH potently (swine ED50 2.3 nmol/kg, against 3.9 nmol/kg for GHRP-6) yet did not raise ACTH or cortisol above the level seen with GHRH alone — even at doses more than 200-fold above its GH ED50. That made it the first highly GH-selective growth hormone secretagogue [1]. The selectivity is not incidental; it is the property the whole compound is organized around. ## Pharmacokinetics: the human numbers The pharmacokinetic profile is the best-characterized human aspect of ipamorelin, and the lead lens of this site. Population PK/PD modeling in healthy male volunteers (n=8 per dose level), using five 15-minute intravenous infusions from 4.21 to 140.45 nmol/kg, found dose-proportional, linear kinetics: terminal half-life approximately 2 hours, clearance 0.078 L/h/kg, and steady-state volume of distribution 0.22 L/kg. The growth-hormone response was a single discrete pulse peaking at about 0.67 hours — near 40 minutes — after dosing [2]. Route matters for this peptide. Ipamorelin itself is not orally bioavailable; engineered analogs derived from it reached only about 10-55% oral bioavailability in dogs, illustrating the structural limits on oral delivery for this class [8]. The half-life and time-course are expanded on the [how long does ipamorelin stay in your system](/half-life) page, and the onset on the [how long does it take for ipamorelin to work](/how-long-to-work) page. ## Preclinical outcomes: bone growth and the 2024 ferret study In adult female Sprague-Dawley rats, subcutaneous ipamorelin at 18, 90, and 450 micrograms per day (divided three times daily for 15 days) dose-dependently raised the longitudinal bone-growth rate from 42 micrometers/day on vehicle to 44, 50, and 52 micrometers/day — with no change in total IGF-1, IGF-binding proteins, or bone-turnover markers, pointing to a partly local, GH-pulse-driven skeletal effect [4]. The most recent published in-vivo study is a 2024 ferret experiment. Intraperitoneal ipamorelin (1-3 mg/kg) inhibited cisplatin-induced body-weight loss by approximately 24% on the last day of the delayed phase (48-72 hours), but had no anti-emetic effect on either acute or delayed cisplatin-induced vomiting — in contrast to centrally administered anamorelin, which reduced acute emesis by 60%. The weight-protective effect appeared to work through a peripheral mechanism [9]. ## Ipamorelin cjc-1295 Ipamorelin cjc-1295 refers to a popular pairing of ipamorelin with CJC-1295, a long-acting analog of growth-hormone-releasing hormone (GHRH). The pharmacological rationale is real and mechanism-based: ipamorelin works through the ghrelin receptor while CJC-1295 works through the GHRH receptor, two complementary pathways that converge on the same GH-releasing cells [1]. In principle, engaging both can produce a larger, more physiological GH pulse than either alone. The critical caveat is evidentiary. There are no controlled trials of the ipamorelin cjc-1295 combination for any outcome. Its support comes entirely from the separate single-agent pharmacology of each peptide, not from any study of the two together. A legitimate reading treats the pairing as plausible class-level pharmacology, not as a tested or proven product. ## Ipamorelin vs sermorelin Ipamorelin vs sermorelin is a comparison of two different receptor mechanisms, not two versions of the same thing. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist — a growth-hormone-releasing peptide [1]. Sermorelin is a GHRH analog: it mimics growth-hormone-releasing hormone and acts on the GHRH receptor. They release GH through distinct, complementary pathways, which is precisely why GHRP and GHRH agents are sometimes studied or used together rather than as substitutes. On the evidence axis, both have thin human outcome data, but their histories differ: ipamorelin was never approved for any indication [3], whereas sermorelin formulations have a different regulatory past. This site is an ipamorelin digest; the sermorelin record is summarized elsewhere and not the subject here. The honest one-line comparison is that they are mechanistically different tools, and neither has a robust controlled-trial base for the anti-aging uses they are marketed for. ## Ipamorelin vs tesamorelin Ipamorelin vs tesamorelin again contrasts a ghrelin-receptor peptide with a GHRH analog. Tesamorelin is a stabilized GHRH analog acting on the GHRH receptor; ipamorelin acts on the separate ghrelin/GHS-R1a receptor to release GH [1]. The mechanisms are complementary rather than interchangeable. The sharpest contrast is regulatory and evidentiary, not mechanistic. Tesamorelin reached approval for a specific, narrow human indication on the strength of controlled trials. Ipamorelin did not: its only Phase 2 trial missed its primary endpoint and it has never been approved anywhere [3]. So a due-diligence comparison reads less as "which peptide is stronger" and more as "which peptide has human outcome evidence behind it" — and on that axis the two are not in the same position. ## Is ipamorelin fda approved Ipamorelin is not FDA approved. It has never been approved as a drug for any indication by the FDA or any other regulatory authority [3]. It was investigated — most notably for postoperative ileus (NCT00672074) — but that Phase 2 trial missed its primary endpoint, and no approval or further clinical program followed. The compounding-access picture tightened recently. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk drug substances list, following the nominator's withdrawal in September 2024, and reviewed ipamorelin acetate and free base at the October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) meeting; it is not an approved bulk substance for compounding [3]. Ipamorelin is marketed only as a research chemical. Separately, it is prohibited in sport at all times under the WADA Prohibited List category S2 (growth hormone secretagogues), and accredited anti-doping laboratories can detect it in urine. ## The anti-doping detection literature A substantial share of the modern ipamorelin literature is analytical — methods to detect it in sport-doping control. Researchers have mapped the structure-activity relationship of GHRPs at GHS-R1a, including ipamorelin, and characterized its urinary metabolites after nasal administration [10]. Ipamorelin has served as a test peptide in validating chemical stabilization mixtures for doping-control urine containers [11], and direct-urine-injection ion-mobility mass spectrometry methods now detect it among 17 other prohibited small peptides at limits of 50-500 pg/mL [12]. The gray market has also generated its own analytical findings. Anti-doping groups identified Gly-Ipamorelin — ipamorelin with an extra N-terminal glycine — as a novel analog in black-market doping products [13], and the same modified analog was later found in pharmaceutical preparations seized by customs [14]. These studies are why ipamorelin is reliably detectable, and they form part of why a "legitimacy" reading exists at all: the substance is both prohibited in sport and traceable. --- A pharmacokinetics-first due-diligence read of the ipamorelin record — the ~2-hour human half-life and the clearance figures logged as the one clean instrument reading, the failed Phase 2 endpoint and the 503A/WADA status entered straight from the register, and the community reports held to one side as unverified; no clinic behind the readout, no endorsement of any seller, and nothing here dosed, prescribed, or sold.